Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis

被引:18
|
作者
Lucas, M
Sánchez-Soliño, O
Solano, F
Izquierdo, G
机构
[1] Virgen Macarena Univ Hosp, Mol Biol Serv, Seville, Spain
[2] Schering Espana SA, Madrid, Spain
[3] Virgen Macarena Univ Hosp, Neurol Serv, Seville, Spain
关键词
D O I
10.1016/S0197-0186(98)00014-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We studied the rate of reactive oxygen species (ROS) production by monocytes 'ex vivo' in a cohort of healthy individuals, in a group of MS patients undergoing treatment with interferon beta-lb and another group of MS patients who refused treatment with interferon beta-1b. The rate of ROS production in healthy individuals was slightly lower than in non-treated MS patients. The lower rate of ROS production was obtained in monocytes of MS patients treated with interferon beta-1b. These results indicate that the treatment of relapsing-remitting MS patients with interferon beta-lb rendered the NADPH oxidase of the monocytes less sensitive to trigger reactive oxygen species (ROS). (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:101 / 102
页数:2
相关论文
共 50 条
  • [31] Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis
    Greenberg, Benjamin M.
    Balcer, Laura
    Calabresi, Peter A.
    Cree, Bruce
    Cross, Anne
    Frohman, Teresa
    Gold, Ralf
    Havrdova, Eva
    Hemmer, Bernhard
    Kieseier, Bernd C.
    Lisak, Robert
    Miller, Aaron
    Racke, Michael K.
    Steinman, Lawrence
    Stuve, Olaf
    Wiendl, Heinz
    Frohman, Elliot
    JAMA NEUROLOGY, 2013, 70 (02) : 248 - 251
  • [32] Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
    O'Rourke, K.
    Walsh, C.
    Antonelli, G.
    Hutchinson, M.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (03) : 336 - 342
  • [33] A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis
    Gulati, A.
    Bagnato, F.
    Villoslada, P.
    de Mendizabal, N. Velez
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2015, 4 (05): : 295 - 304
  • [34] Interferon-beta and disability progression in relapsing-remitting multiple sclerosis
    Drulovic, Jelena
    Kostic, Jelena
    Mesaros, Sarlota
    Basuroski, Irena Dujmovic
    Stojsavljevic, Nebojsa
    Kisic-Tepavcevic, Darija
    Pekmezovic, Tatjana
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S65 - S69
  • [35] The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis
    Madsen, Claus
    BRAIN AND BEHAVIOR, 2017, 7 (06):
  • [36] Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 759 - 766
  • [37] Clinical significance of antibodies to interferon beta therapy in patients with relapsing-remitting multiple sclerosis
    Bendtzen, Klaus
    CYTOKINE, 2009, 48 (1-2) : 21 - 21
  • [38] EFFECTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS TREATMENT WITH INTERFERON BETA-1B RESULTS OF A THREE-YEAR FOLLOW-UP STUDY
    Jesic, Aleksandar
    Stefanovic, Dragana
    Delibasic, Nenad
    Semnic, Marija
    Sakallasz, Lorand
    Dobrenov, Dragica
    Zivanovic, Zeljko
    Rabi-Zikic, Tamara
    Zikic, Milorad
    ACTA CLINICA CROATICA, 2009, 48 (02) : 183 - 186
  • [39] Side effects of interferon beta in a group of 45 patients with relapsing-remitting multiple sclerosis
    Radulovic, L.
    Vujisic, S.
    Milovic, Z.
    Vukovic, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 497 - 497
  • [40] Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis
    Munschauer, FE
    Kinkel, RP
    CLINICAL THERAPEUTICS, 1997, 19 (05) : 883 - 893